PPMS patients taking Ocrevus are less likely to see progression
Having recently concluded an ORATORIO phase III clinical trial of primary progressive multiple sclerosis (PPMS) patients, Genentech’s Ocrevus (ocrelizumab) increased the number of patients found to have no experienced progression (NEP) when taking the drug...Read more - http://www.ms-uk.org/ppms-patients-taki ... ion-100317
PPMS patients taking Ocrevus are less likely to progress...
PPMS patients taking Ocrevus are less likely to progress...
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2092 Views
-
Last post by NHE
-
- 0 Replies
- 977 Views
-
Last post by NHE
-
- 0 Replies
- 10076 Views
-
Last post by NHE
-
- 0 Replies
- 1993 Views
-
Last post by Firidion
-
- 1 Replies
- 1347 Views
-
Last post by vesta
-
- 0 Replies
- 2019 Views
-
Last post by frodo
-
- 0 Replies
- 1928 Views
-
Last post by NHE
-
- 0 Replies
- 1493 Views
-
Last post by NHE
-
- 4 Replies
- 2444 Views
-
Last post by JohnC777